Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis

Gastroenterology Research and Practice

Volumn 2015, Issue , 2015, Pages

  Liu, Xiaoqun ^a   Wang, Hui ^a   Lv, Zhifa ^a   Wang, Youhua ^a   Wang, Ben ^a   Xie, Yong ^a   Zhou, Xiaojiang ^a   Lv, Nonghua ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN; TETRACYCLINE;

BACTERIAL CLEARANCE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; META ANALYSIS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84935904897     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2015/415648     Document Type: Review

References (66)

1. X. Calvet, M.-J. R. Lázaro, P. Lehours, and F. Mégraud, "Diagnosis and epidemiology of Helicobacter pylori infection", Helicobacter, vol. 18, supplement 1, pp. 5-11, 2013.
2. R. P. Blankfield, A. Zullo, C. Hassan et al., "Helicobacter pylori infection and the development of gastric cancer", The New England Journal of Medicine, vol. 346, no. 1, pp. 65-67, 2002.
3. D. Y. Graham and L. Fischbach, "Helicobacter pylori infection", The New England Journal of Medicine, vol. 363, no. 6, pp. 595-596, 2010.
4. P. Malfertheiner, F. Megraud, C. O'Morain et al., "Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG)", European Journal of Gastroenterology and Hepatology, vol. 9, no. 1, pp. 1-2, 1997.
5. K. M. Fock, P. Katelaris, K. Sugano et al., "Second Asia-pacific consensus guidelines for helicobacter pylori infection", Journal of Gastroenterology and Hepatology, vol. 24, no. 10, pp. 1587-1600, 2009.
6. F. Megraud, S. Coenen, A. Versporten et al., "Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption", Gut, vol. 62, no. 1, pp. 34-42, 2013.
7. V. de Francesco, F. Giorgio, C. Hassan et al., "Worldwide H. pylori antibiotic resistance: a systematic review", Journal of Gastrointestinal and Liver Diseases, vol. 19, no. 4, pp. 409-414, 2010.
8. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., "Management of Helicobacter pylori infection-the Maastricht IV/Florence consensus report", Gut, vol. 61, no. 5, pp. 646-664, 2012.
9. T. J. Borody, G. Pang, A. R. Wettstein et al., "Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection", Alimentary Pharmacology and Therapeutics, vol. 23, no. 4, pp. 481-488, 2006.
10. J. P. Gisbert, M. Castro-Fernandez, A. Perez-Aisa et al., "Fourthline rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures", Alimentary Pharmacology and Therapeutics, vol. 35, no. 8, pp. 941-947, 2012.
11. J. P. Gisbert and X. Calvet, "Review article: rifabutin in the treatment of refractory Helicobacter pylori infection", Alimentary Pharmacology and Therapeutics, vol. 35, no. 2, pp. 209-221, 2012.
12. A. Liberati, D. G. Altman, J. Tetzlaff et al., "The PRISMA statement for reporting systematic reviews andmeta-analyses of studies that evaluate healthcare interventions: explanation and elaboration", BMJ, vol. 339, p. b2700, 2009.
13. D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement", BMJ, vol. 339, Article ID b2535, 2009.
14. G. Fiorini, N. Vakil, A. Zullo et al., "Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection", Clinical Gastroenterology and Hepatology, vol. 11, no. 5, pp. 507-510, 2013.
15. J. M. Navarro-Jarabo, N. Fernández, F. L. Sousa et al., "Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate Helicobacter pylori infection", BMC Gastroenterology, vol. 7, article 31, 2007.
16. S. Miehlke, K. Hansky, W. Schneider-Brachert et al., "Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin", Alimentary Pharmacology and Therapeutics, vol. 24, no. 2, pp. 395-403, 2006.
17. A. Qasim, S. Sebastian, O. Thornton et al., "Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients", Alimentary Pharmacology and Therapeutics, vol. 21, no. 1, pp. 91-96, 2005.
18. J. P. Gisbert, J. L. Gisbert, S. Marcos, R. Moreno-Otero, and J. M. Pajares, "Third-line rescue therapy with levofloxacin ismore effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures", Alimentary Pharmacology and Therapeutics, vol. 24, no. 10, pp. 1469-1474, 2006.
19. F. Perri, V. Festa, R. Clemente et al., "Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies", American Journal of Gastroenterology, vol. 96, no. 1, pp. 58-62, 2001.
20. J. P. Gisbert, J. L. Gisbert, S. Marcos, and J. M. Pajares, "Empirical Helicobacter pylori 'rescue' therapy after failure of two eradication treatments", Digestive and Liver Disease, vol. 36, no. 1, pp. 7-12, 2004.
21. J. P. Gisbert, J.-L. Gisbert, S. Marcos, I. Jimenez-Alonso, R. Moreno-Otero, and J. M. Pajares, "Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year singlecentre study of 500 patients", Alimentary Pharmacology and Therapeutics, vol. 27, no. 4, pp. 346-354, 2008.
22. S. Toracchio, S. Capodicasa, D. B. Soraja, L. Cellini, and L. Marzio, "Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin", Digestive and Liver Disease, vol. 37, no. 1, pp. 33-38, 2005.
23. J. P. Gisbert, X. Calvet, L. Bujanda, S. Marcos, J. L. Gisbert, and J.M. Pajares, "'Rescue' therapy with rifabutin aftermultiple Helicobacter pylori treatment failures", Helicobacter, vol. 8, no. 2, pp. 90-94, 2003.
24. P. González Carro, F. Pérez Roldán, A. De Pedro Esteban et al., "Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments", Journal of Gastroenterology and Hepatology, vol. 22, no. 1, pp. 60-63, 2007.
25. S. Veldhuyzen van Zanten, S. Desai, L. Best et al., "Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection", Canadian Journal of Gastroenterology, vol. 24, no. 5, pp. 303-306, 2010.
26. F. Perri, V. Festa, R. Clemente, M. Quitadamo, and A. Andriulli, "Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens", Alimentary Pharmacology and Therapeutics, vol. 14, no. 3, pp. 311-316, 2000.
27. H. Bock, H. Koop, N. Lehn, and M. Heep, "Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience", Journal of Clinical Gastroenterology, vol. 31, no. 3, pp. 222-225, 2000.
28. A. Zullo, V. de Francesco, G. Manes, G. Scaccianoce, F. Cristofari, and C. Hassan, "Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice", Journal of Gastrointestinal and Liver Diseases, vol. 19, no. 2, pp. 131-134, 2010.
29. D. Van der Poorten and P. H. Katelaris, "The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice", Alimentary Pharmacology and Therapeutics, vol. 26, no. 11-12, pp. 1537-1542, 2007.
30. F. Perri, V. Festa, R. Clemente et al., "Rifabutin-based treatment as 'rescue therapy' for H. Pylori infected patients after failure of standard regimens: a pilot study", Gastroenterology, vol. 114, supplement 1, p. A257, 1998.
31. J. P. Gisbert, M. Castro-Fernandez, A. P. Aisa et al., "Fourthline rescue therapywith rifabutin in patients with three H. Pylori eradication failures", Gastroenterology, vol. 146, no. 5, p. S-395, 2014.
32. T. Borody, G. Agrawal, J. Campbell, and et al, "Rescue H. Pylori therapy in the clinical setting", American Journal of Gastroenterology, vol. 107, p. S594, 2012.
33. B. S. Moon, H. C. Lim, Y. C. Lee et al., "Efficacy of rifabutin based triple therapy including high dose ppi and amoxicillin for third line rescue therapy of Helicobacter pylori", Helicobacter, vol. 17, p. 105, 2012.
34. K. Slim, E. Nini, D. Forestier, F. Kwiatkowski, Y. Panis, and J. Chipponi, "Methodological index for non-randomized studies (Minors): development and validation of a new instrument", ANZ Journal of Surgery, vol. 73, no. 9, pp. 712-716, 2003.
35. W. M. Wong, O. Gu, S. K. Lam et al., "Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection", Alimentary Pharmacology and Therapeutics, vol. 17, no. 4, pp. 553-560, 2003.
36. S. Miehlke, W. Schneider-Brachert, C. Kirsch et al., "One-week once-daily triple therapy with esomeprazole, Moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin", Helicobacter, vol. 13, no. 1, pp. 69-74, 2008.
37. P. Basu, N. Shah, M. D. Rahaman et al., "omeprazole, alinia, and doxycycline therapy for prior treatment failure Helicobacter pylori population: a randomized, open-label clinical pilot study road trial", American Journal of Gastroenterology, vol. 108, article S49, 2013.
38. P. Basu, N. J. Shah, K. Mittimani et al., "Rifabutin, omeprazole, alinia and doxycycline therapy for prior treatment failure Helicobacter pylori (HP) population-a randomized open label clinical pilot study-road trial", Gastroenterology, vol. 144, no. 5, p. S336, 2013.
39. S. P. Yun, H. G. Seon, C. S. Ok et al., "Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori", Gut and Liver, vol. 6, no. 4, pp. 452-456, 2012.
40. M. M. D'Elios, E. Silvestri, G. Emmi, T. Barnini, and D. Prisco, "Helicobacter pylori: usefulness of an empirical fourth-line rifabutin-based regimen", Expert Review of Gastroenterology and Hepatology, vol. 6, no. 4, pp. 437-439, 2012.
41. D. Burgos-Santamaria, A. G. McNicholl, J. Gisbert et al., "Su1169 Empirical rescue therapy after H. Pylori treatment failure. A 15-year single center study of 1,000 patients", Gastroenterology, vol. 146, no. 5, p. S-394, 2014.
42. M. H. Jeong, J. W. Chung, S. J. Lee et al., "Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori", The Korean Journal of Gastroenterology, vol. 59, no. 6, pp. 401-406, 2012.
43. J. P. Gisbert, M. Castro-Fernandez, A. P. Aisa et al., "Fourthline rescue therapywith rifabutin in patients with three H. Pylori eradication failures", Gastroenterology, vol. 140, no. 5, p. S878, 2011.
44. J. P. Gisbert, M. Castro-Fernandez, A. P. Aisa et al., "Fourth-line rescue therapy with rifabutin in patients with three H. Pylori eradication failures", Gastroenterology, vol. 144, no. 5, p. S334, 2013.
45. S. Miehlke, K. Hansky, W. Schneider-Brachert et al., "Sevenday triple therapy with esomeprazole, rifabutin and amoxicillin is effective in eradicating Helicobacter pylori resistant to both metronidazole and clarithromycin-a prospective, randomized multicenter trial", Gastroenterology, vol. 124, supplement 1, no. 4, p. A359, 2003.
46. S. Miehlke, K. Hansky, W. Schneider-Brachert et al., "One-week triple therapy with esomeprazole, rifabutin and amoxicillin is effective for eradication of Helicobacter pylori resistant to both metronidazole and clarithromycin", Gastroenterology, vol. 128, no. 4, p. A64, 2005.
47. K.M. Fock, P. Katelaris, K. Sugano et al., "Second Asia-Pacific consensus guidelines for Helicobacter pylori infection", Journal of Gastroenterology and Hepatology, vol. 24, no. 10, pp. 1587-1600, 2009.
48. W.D. Chey and B. C. Y. Wong, "American College of Gastroenterology guideline on the management of Helicobacter pylori infection", American Journal of Gastroenterology, vol. 102, no. 8, pp. 1808-1825, 2007.
49. S. M. Smith, R. B. Haider, H. O'Connor et al., "Practical treatment of Helicobacter pylori: a balanced view in changing times", European Journal of Gastroenterology & Hepatology, vol. 26, no. 8, pp. 819-825, 2014.
50. R. Piccolomini, G. Di Bonaventura, C. Picciani, F. Laterza, J. Vecchiet, and M. Neri, "In vitro activity of clarithromycin against intracellular Helicobacter pylori", Antimicrobial Agents and Chemotherapy, vol. 45, no. 5, pp. 1568-1571, 2001.
51. A. O'Connor, I. Taneike, A. Nami et al., "Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre", Irish Journal of Medical Science, vol. 182, no. 4, pp. 693-695, 2013.
52. M. M. Biernat, E. Poniewierka, J. Błaszczuk et al., "Antimicrobial susceptibility of Helicobacter pylori isolates from Lower Silesia, Poland", Archives of Medical Science, vol. 10, no. 3, pp. 505-509, 2014.
53. D. Y. Graham, Y.-C. Lee, and M.-S. Wu, "Rational Helicobacter pylori therapy: evidence-based medicine rather than medicinebased evidence", Clinical Gastroenterology and Hepatology, vol. 12, no. 2, pp. 177-186, 2014.
54. J. K. Akada, M. Shirai, K. Fujii, K. Okita, and T. Nakazawa, "In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657", Antimicrobial Agents and Chemotherapy, vol. 43, no. 5, pp. 1072-1076, 1999.
55. G. Rossi, "An update on the antibiotic therapy of tuberculosis", Recenti Progressi in Medicina, vol. 90, no. 5, pp. 241-243, 1999.
56. J.-Y. Wu, J.-M. Liou, and D. Y. Graham, "Evidence-based recommendations for successful Helicobacter pylori treatment", Expert Review of Gastroenterology and Hepatology, vol. 8, no. 1, pp. 21-28, 2014.
57. L. Gao, H.-P. Xiao, Z.-Y. Hu, Z.-L. Cui, J.-M. Lu, and X.-N. Shen, "Cross-resistance between rifampin and rifabutin inmultidrug resistant Mycobacterium tuberculosis complex strains", Zhonghua Jie He He Hu Xi Za Zhi, vol. 35, no. 5, pp. 333-335, 2012.
58. F. B. Jamieson, J. L. Guthrie, A. Neemuchwala, O. Lastovetska, R. G. Melano, and C. Mehaffy, "Profiling of rpo Bmutations and MICs for rifampin and rifabutin in mycobacterium tuberculosis", Journal of Clinical Microbiology, vol. 52, no. 6, pp. 2157-2162, 2014.
59. G. Apseloff, "Severe neutropenia among healthy volunteers given rifabutin in clinical trials", Clinical Pharmacology and Therapeutics, vol. 74, no. 6, pp. 591-592, 2003.
60. J. Jetton, J. G. Gaviria, T. F. Patterson, and D. A. Johnson, "Rifabutin-associated uveitis in an immunocompetent individual with Mycobacterium simiae", Canadian Journal of Ophthalmology, vol. 44, no. 4, pp. 468-469, 2009.
61. W. M. Smith, M. G. Reddy, K. A. Hutcheson, R. J. Bishop, and H. N. Sen, "Rifabutin-associated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia", Journal of Ophthalmic Inflammation and Infection, vol. 2, no. 3, pp. 149-152, 2012.
62. J.-Y. Chien, S.-T. Chien, S.-Y. Huang, and C.-J. Yu, "Safety of rifabutin replacing rifampicin in the treatment of tuberculosis: a single-centre retrospective cohort study", Journal of Antimicrobial Chemotherapy, vol. 69, no. 3, pp. 790-796, 2014.
63. C. Pochat-Cotilloux, F. De Bats, A.M. Nguyen et al., "Rifabutinassociated bilateral uveitis: a case report", Journal Français d'Ophtalmologie, vol. 37, no. 8, pp. e115-e117, 2014.
64. D. E. Griffith, B. A. Brown, W. M. Girard, and R. J. Wallace Jr., "Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacteriumavium complex lungdisease", Clinical Infectious Diseases, vol. 21, no. 3, pp. 594-598, 1995.
65. G. Apseloff, G. Foulds, L. LaBoy-Goral, E. Kraut, and J. Vincent, "Severe neutropenia caused by recommended prophylactic doses of rifabutin", The Lancet, vol. 348, no. 9028, p. 685, 1996.
66. F. di Mario, L. G. Cavallaro, and C. Scarpignato, "'Rescue' therapies for the management of Helicobacter pylori infection", Digestive Diseases, vol. 24, no. 1-2, pp. 113-130, 2006.